Suppr超能文献

玻璃体后脱离与视网膜母细胞瘤玻璃体内注射美法仑治疗相关的视网膜毒性风险

Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma.

作者信息

Berry Jesse L, Lee Ramon, Patel Luv, Le Bao Han A, O'Fee John, Jubran Rima, Kim Jonathan W

机构信息

USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.

The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.

出版信息

Ocul Oncol Pathol. 2019 Jun;5(4):238-244. doi: 10.1159/000493687. Epub 2018 Nov 2.

Abstract

BACKGROUND/AIMS: The presence of a posterior vitreous detachment (PVD) may play a role in the development of severe retinal toxicity following intravitreal melphalan (IVM) injection for vitreous seeding. We aimed to evaluate the incidence of PVD in retinoblastoma eyes and its association with retinal toxicity after IVM.

METHODS

We reviewed 112 eyes of 81 retinoblastoma patients with B-scan images available for review from 2010 to 2017. A cohort with vitreous seeding treated with IVM was compared to a cohort that did not undergo injection. The primary outcome measure was the presence of PVD at diagnosis and after treatment. Secondary measures included IVM-associated retinal toxicity and other ocular complications.

RESULTS

The incidence of PVD was 20% at diagnosis, and in eyes with B-scans available both at diagnosis and after treatment 18% of eyes developed a PVD over the course of therapy, more frequently after IVM ( = 0.05). Of 34 eyes receiving IVM treatment, the incidences of posterior segment toxicity and globe salvage were similar between eyes with and without PVD ( = 0.4015 and 0.52, respectively).

CONCLUSION

In this cohort of patients, there did not appear to be an association with the presence of PVD during IVM and the development of retinal toxicity.

摘要

背景/目的:玻璃体后脱离(PVD)的存在可能在玻璃体内注射美法仑(IVM)治疗玻璃体种植后严重视网膜毒性的发生中起作用。我们旨在评估视网膜母细胞瘤患者眼中PVD的发生率及其与IVM后视网膜毒性的相关性。

方法

我们回顾了2010年至2017年81例视网膜母细胞瘤患者的112只眼睛,这些眼睛有可供复查的B超图像。将接受IVM治疗玻璃体种植的队列与未接受注射的队列进行比较。主要观察指标是诊断时和治疗后PVD的存在情况。次要指标包括IVM相关的视网膜毒性和其他眼部并发症。

结果

诊断时PVD的发生率为20%,在诊断时和治疗后均有B超图像的眼睛中,18%的眼睛在治疗过程中出现了PVD,IVM后更常见(P = 0.05)。在接受IVM治疗的34只眼睛中,有PVD和无PVD的眼睛后段毒性和眼球挽救率相似(分别为P = 0.4015和0.52)。

结论

在该队列患者中,IVM期间PVD的存在与视网膜毒性的发生之间似乎没有关联。

相似文献

2
Ocriplasmin for symptomatic vitreomacular adhesion.
Cochrane Database Syst Rev. 2017 Oct 17;10(10):CD011874. doi: 10.1002/14651858.CD011874.pub2.
4
Laser therapy for retinopathy in sickle cell disease.
Cochrane Database Syst Rev. 2015 Oct 9;2015(10):CD010790. doi: 10.1002/14651858.CD010790.pub2.
5
Laser therapy for retinopathy in sickle cell disease.
Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3.
7
Surgical interventions for bilateral congenital cataract in children aged two years and under.
Cochrane Database Syst Rev. 2022 Sep 15;9(9):CD003171. doi: 10.1002/14651858.CD003171.pub3.
8
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2.
9
Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.
Br J Ophthalmol. 2014 Mar;98(3):292-7. doi: 10.1136/bjophthalmol-2013-303885. Epub 2013 Nov 1.
10
Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy.
Cochrane Database Syst Rev. 2014 Feb 14;2(2):CD006126. doi: 10.1002/14651858.CD006126.pub3.

引用本文的文献

1
Vitreous Seed Classification and Regression Patterns in Eyes With Retinoblastoma.
J Vitreoretin Dis. 2020 Sep 21;5(2):121-129. doi: 10.1177/2474126420951980. eCollection 2021 Mar-Apr.
2
A Rare Case of Acute Hemorrhagic Retinopathy Following Intravitreal Melphalan Injection for Persistent Vitreous Seeds in Retinoblastoma.
J Vitreoretin Dis. 2021 Jul 26;6(2):155-157. doi: 10.1177/24741264211024147. eCollection 2022 Mar-Apr.
3
Intravitreal Melphalan for Retinoblastoma: The Impact of Toxicity on Recurrence and Ultimate Globe Salvage.
Ocul Oncol Pathol. 2020 Dec;6(6):388-394. doi: 10.1159/000509080. Epub 2020 Aug 25.
5
Commentary: Current standards in retinoblastoma care.
Indian J Ophthalmol. 2020 Nov;68(11):2367. doi: 10.4103/ijo.IJO_3198_20.

本文引用的文献

1
Loss of fundus view as an indication for secondary enucleation in retinoblastoma.
Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26908. Epub 2017 Dec 8.
2
Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Ophthalmology. 2017 Dec;124(12):1817-1825. doi: 10.1016/j.ophtha.2017.05.034. Epub 2017 Jun 24.
4
Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.
Ophthalmology. 2017 Apr;124(4):488-495. doi: 10.1016/j.ophtha.2016.12.015. Epub 2017 Jan 12.
6
Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age.
Ocul Oncol Pathol. 2015 Feb;1(2):103-10. doi: 10.1159/000370215. Epub 2015 Jan 16.
7
Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model.
J Ocul Pharmacol Ther. 2016 May;32(4):230-5. doi: 10.1089/jop.2015.0088. Epub 2016 Jan 19.
9
Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma.
JAMA Ophthalmol. 2015 Dec;133(12):1459-63. doi: 10.1001/jamaophthalmol.2015.3119.
10
The role of intravitreal chemotherapy for retinoblastoma.
Indian J Ophthalmol. 2015 Feb;63(2):141-5. doi: 10.4103/0301-4738.154390.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验